Article Text

PDF
THU0352 Long-Term Safety and Efficacy of Golimumab in the Treatment of Ankylosing Spondylitis: Results Through 5 Years of the Go-Raise Trial
  1. A. Deodhar1,
  2. J. Braun2,
  3. R. Inman3,
  4. D. van der Heijde4,
  5. Y. Zhou5,
  6. B. Hsu5
  1. 1Oregon Health & Science Univ, Portland, United States
  2. 2Rheumazentrum Ruhrgebiet/Ruhr-University Bochum, Herne, Germany
  3. 3Univ of Toronto, Toronto, Canada
  4. 4Leiden Univ Medical Center, Leiden, Netherlands
  5. 5Janssen R&D, LLC, Spring House, United States

Abstract

Background Golimumab(GLM) has demonstrated significant and sustained clinical efficacy and an acceptable safety profile through 2yrs of the phase 3, randomized, PBO-controlled, GO-RAISE study in pts with ankylosing spondylitis (AS).

Objectives To evaluate GLM safety/efficacy in AS pts receiving GLM50mg and/or 100mg through 5yrs.

Methods 356pts with AS were randomized to SC PBO, GLM50mg, or GLM100mg q4w. At wk16, pts with inadequate response early escaped (EE) with blinded dose adjustments (PBO→GLM50mg, GLM50mg→ 100mg). At wk24, pts still receiving PBO crossed over to GLM50mg. Pts continued double-blind treatment through wk100. The long-term extension started with the wk104 GLM injection. Pts received GLM q4w for ~5yrs (final injection at wk252). After unblinding at wk104 and at the investigator’s discretion, pts receiving GLM50mg could increase their dose to 100mg; pts receiving GLM100mg could decrease dose to 50mg; concomitant DMARD, corticosteroid, and NSAID therapy could be adjusted.

Results Among 356 randomized pts, 254 pts continued treatment through wk252; 242 completed the safety follow-up through wk268. 101 pts withdrew (33 [9.3%] due to AEs, 35 [9.8%] lack of efficacy, 11 [3.1%] lost to follow-up, 22 [6.2%] for other reasons); 1pt was untreated. Reductions in AS-related signs/symptoms and improvements in physical function and range of motion observed at wk14 (primary endpoint visit; previously reported) were maintained through 5yrs (Table). Serious AEs were reported for 17.1% of GLM50mg, 24.7% of GLM100mg, and 22.0% of all GLM-treated pts. One pt died (GLM50mg, B cell lymphoma after 3yrs in the study, followed by pancreatic cancer).

Conclusions In pts with active AS, SC GLM50 and 100mg q4w improved AS signs/symptoms, physical function, and range of motion and demonstrated an acceptable safety profile that was consistent with previously reported results for GLM through wk160 and with other anti-TNF biologics. There were no differences between the two GLM dosages.

Disclosure of Interest A. Deodhar Grant/research support from: Janssen R&D, LLC, J. Braun Grant/research support from: Janssen R&D, LLC, R. Inman Grant/research support from: Janssen R&D, LLC, D. van der Heijde Grant/research support from: Janssen R&D, LLC, Y. Zhou Shareholder of: Johnson & Johnson, Employee of: Janssen R&D, LLC, B. Hsu Shareholder of: Johnson & Johnson, Employee of: Janssen R&D, LLC

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.